Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CMND NYSE:OGEN NASDAQ:ORGS NASDAQ:QLGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMNDClearmind Medicine$1.02-2.9%$1.02$0.80▼$2.18$4.48M0.9735,572 shs21,504 shsOGENOragenics$1.21+5.2%$1.24$1.01▼$18.90$4.75M0.82308,793 shs235,769 shsORGSOrgenesis$0.90-5.3%$0.65$0.00▼$6.40$4.32M3.196,764 shs100 shsQLGNQualigen Therapeutics$2.10+0.5%$2.33$1.61▼$10.45$3.54M-0.1542,570 shs24,867 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMNDClearmind Medicine-2.86%-0.97%0.00%+18.74%-21.54%OGENOragenics+5.22%+12.04%+5.22%-72.25%-91.93%ORGSOrgenesis-5.26%+429.41%+3,990.91%-53.85%+89,999,900.00%QLGNQualigen Therapeutics+0.48%+24.26%+25.75%-43.40%-72.90%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMNDClearmind Medicine$1.02-2.9%$1.02$0.80▼$2.18$4.48M0.9735,572 shs21,504 shsOGENOragenics$1.21+5.2%$1.24$1.01▼$18.90$4.75M0.82308,793 shs235,769 shsORGSOrgenesis$0.90-5.3%$0.65$0.00▼$6.40$4.32M3.196,764 shs100 shsQLGNQualigen Therapeutics$2.10+0.5%$2.33$1.61▼$10.45$3.54M-0.1542,570 shs24,867 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMNDClearmind Medicine-2.86%-0.97%0.00%+18.74%-21.54%OGENOragenics+5.22%+12.04%+5.22%-72.25%-91.93%ORGSOrgenesis-5.26%+429.41%+3,990.91%-53.85%+89,999,900.00%QLGNQualigen Therapeutics+0.48%+24.26%+25.75%-43.40%-72.90%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCMNDClearmind Medicine 0.00N/AN/AN/AOGENOragenics 0.00N/AN/AN/AORGSOrgenesis 0.00N/AN/AN/AQLGNQualigen Therapeutics 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCMNDClearmind MedicineN/AN/AN/AN/A$0.73 per shareN/AOGENOragenicsN/AN/AN/AN/A$0.61 per shareN/AORGSOrgenesis$662K6.52N/AN/A($6.58) per share-0.14QLGNQualigen TherapeuticsN/AN/AN/AN/A($4.12) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCMNDClearmind Medicine-$5.26M-$1.10N/A∞N/AN/A-147.22%-63.96%9/15/2025 (Estimated)OGENOragenics-$20.66M-$21.42N/A∞N/AN/A-2,087.95%-486.56%N/AORGSOrgenesis-$55.36MN/A0.00∞N/A-3,827.81%N/A-130.18%11/11/2025 (Estimated)QLGNQualigen Therapeutics-$6.26MN/A0.00∞N/AN/AN/A-202.16%11/12/2025 (Estimated)Latest OGEN, ORGS, CMND, and QLGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/11/2025Q3 2025CMNDClearmind MedicineN/A-$0.25N/A-$0.25N/AN/A8/14/2025Q2 2025QLGNQualigen TherapeuticsN/A-$1.00N/A-$1.00N/AN/A7/21/2025Q1 2025QLGNQualigen TherapeuticsN/A-$1.82N/A-$1.82N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCMNDClearmind MedicineN/AN/AN/AN/AN/AOGENOragenicsN/AN/AN/AN/AN/AORGSOrgenesisN/AN/AN/AN/AN/AQLGNQualigen TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCMNDClearmind MedicineN/A1.741.74OGENOragenicsN/A1.931.93ORGSOrgenesisN/A0.070.07QLGNQualigen TherapeuticsN/A0.710.71Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCMNDClearmind Medicine96.05%OGENOragenics18.71%ORGSOrgenesis22.56%QLGNQualigen Therapeutics3.18%Insider OwnershipCompanyInsider OwnershipCMNDClearmind MedicineN/AOGENOragenics4.90%ORGSOrgenesis5.66%QLGNQualigen Therapeutics1.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCMNDClearmind MedicineN/A4.27 millionN/ANot OptionableOGENOragenics54.13 million10.98 millionN/AORGSOrgenesis1504.80 million4.53 millionNo DataQLGNQualigen Therapeutics501.70 million1.66 millionNot OptionableOGEN, ORGS, CMND, and QLGN HeadlinesRecent News About These CompaniesFinancial Analysis: TherapeuticsMD (NASDAQ:TXMD) versus Qualigen Therapeutics (NASDAQ:QLGN)September 4, 2025 | americanbankingnews.comQualigen Therapeutics Amends Promissory Note with MarizymeAugust 27, 2025 | tipranks.comQualigen Therapeutics, Inc.: Qualigen Therapeutics Provides Update on Nasdaq Communications and Continued Listing StatusJuly 30, 2025 | finanznachrichten.deQualigen Therapeutics Announces $4.5M Private PlacementJuly 29, 2025 | msn.comQualigen Therapeutics provides update on Nasdaq listing statusJuly 28, 2025 | msn.comQualigen Therapeutics Secures Nasdaq Compliance ExtensionJuly 28, 2025 | msn.comQualigen Therapeutics Provides Update on Nasdaq Communications and Continued Listing StatusJuly 28, 2025 | finance.yahoo.comQualigen Therapeutics, Inc. Secures $4.5 Million Through Series A-3 Preferred Stock Private PlacementJuly 28, 2025 | quiverquant.comQQualigen Therapeutics Announces $4.5 Million Private Placement of Series A-3 Convertible Preferred StockJuly 28, 2025 | globenewswire.comQualigen Granted New Patents Covering 25 CountriesJuly 16, 2025 | manilatimes.netMQualigen Therapeutics shares surge after patent approvals in 25 countriesJuly 16, 2025 | msn.comQualigen Therapeutics, Inc. (QLGN) - Yahoo FinanceJune 25, 2025 | finance.yahoo.comQualigen Therapeutics faces potential Nasdaq delistingMay 21, 2025 | uk.investing.comQualigen Therapeutics, Inc. receives expected notification of deficiency from Nasdaq related to ...May 19, 2025 | gurufocus.comQualigen Therapeutics, Inc. receives expected notification of deficiency from Nasdaq related to ...May 19, 2025 | gurufocus.comQualigen Therapeutics, Inc. receives expected notification of deficiency from Nasdaq related to ...May 19, 2025 | gurufocus.comQualigen Therapeutics Faces Nasdaq Delisting NotificationMay 19, 2025 | tipranks.comQualigen Therapeutics, Inc. Faces Potential Delisting from Nasdaq Due to Filing DeficiencyMay 19, 2025 | quiverquant.comQQualigen Therapeutics, Inc. receives expected notification of deficiency from Nasdaq related to delayed filing of quarterly report on Form 10-QMay 19, 2025 | globenewswire.comMarizyme, Inc. (MRZM) Latest Press Releases & Corporate News - Yahoo FinanceMay 10, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOGEN, ORGS, CMND, and QLGN Company DescriptionsClearmind Medicine NASDAQ:CMND$1.02 -0.03 (-2.86%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$1.03 +0.01 (+0.98%) As of 09/12/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Clearmind Medicine Inc., a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors. The company also develops MEAI compound which is in IND-enabling study for the treatment of alcohol use disorder; and is in pre-clinical study for treatment of obesity, weight loss, metabolic disorder, and addiction. In addition, it has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome; and with Yissum Research Development Company of the Hebrew University of Jerusalem for the discovery and development of novel psychedelic-derived therapeutics to treat mental disorders. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.Oragenics NYSE:OGEN$1.21 +0.06 (+5.22%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$1.22 +0.01 (+0.50%) As of 09/12/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Oragenics, Inc., a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.Orgenesis NASDAQ:ORGS$0.90 -0.05 (-5.26%) As of 09/12/2025 10:21 AM EasternOrgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. The company also provides development services, including regulatory services, pre-clinical studies, intellectual property services, and GMP process translation, as well as support services; hospital services; cell process development services; and distributed cell processing services. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland.Qualigen Therapeutics NASDAQ:QLGN$2.10 +0.01 (+0.48%) Closing price 09/12/2025 03:58 PM EasternExtended Trading$2.10 +0.00 (+0.24%) As of 09/12/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Qualigen Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
